Eric van der Helm

Blogging at | Science @SNIPRBiome l Previous at the Novo Nordisk Foundation Center for Biosustainability in @Sommergroup | #synbio

[Eric van der Helm @EricvdHelm]

Last month, @groendahl and I joined @CARB_X Investor Day in Munich ahead of @ESCMID Global. Always energizing to be among so many teams pushing #AMR innovation forward; from early discovery to clinical-stage programs.

[Eric van der Helm @EricvdHelm]

Proud to share our final positive Phase 1 results for SNIPR001 in @LancetMicrobe. Huge thanks to the @sniprbiome team & collaborators. We're using CRISPR to precisely target harmful E. coli bacteria in the gut - helping protect transplant patients from life-threatening infections

[SNIPR @sniprbiome]

Today, we're excited to announce the publication of final Phase 1 results for SNIPR001, our CRISPR therapeutic designed to precisely reduce E. coli in the gut — including multi-drug resistant strains — while preserving healthy gut bacteria.

[Eric van der Helm @EricvdHelm]

Looking forward to speak in Basel

[SNIPR @sniprbiome]

We’re excited to share real-world lessons from building and translating CRISPR-based antimicrobials - what’s worked, what hasn’t, and what it takes to move from promise to patient impact at the 10th @AMR_Conference . Come meet @EricvdHelm in Basel.

[Eric van der Helm @EricvdHelm]

Heading to London for the ⁦@Jefferies⁩ Global Healthcare Conference Nov 17–20. ⁦@sniprbiome⁩ will be on-site, together w. ⁦@groendahl⁩. We’re excited to share insights on our proprietary CRISPR platform and our differentiated #AMR pipeline.

#JefferiesHealthcare

[Eric van der Helm @EricvdHelm]

I couldn’t be prouder of the SNIPR team today! We’ve just closed a €35 million Series B to push the boundaries of antimicrobial therapy. Huge thanks to our investors, partners, and team members that were part of this journey.

[SNIPR @sniprbiome]

We proudly announced the close of a €35 million Series B financing! Learn more about this milestone in the press release below. #AMR #CRISPR #SeriesB

[Eric van der Helm @EricvdHelm]

Very proud to see our lead asset now being dosed in patients for the first time. Big congrats to the whole team!

[SNIPR @sniprbiome]

📢 SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer— the first CRISPR-armed phage therapeutic designed to target E. coli in the gut.
@CARB_X

[SNIPR @sniprbiome]

Looking forward to meeting at #BIO2025! Reach out if you'd like to connect with @groendahl and @EricvdHelm in Boston June 16-19. DM here or email [email protected]

[SNIPR @sniprbiome]

@groendahl and @EricvdHelm will be attending next week's #BioEquity in Bruges🇧🇪.

Reach out to learn more about our recent progress and updates of our pipeline.
#partnering #BioEquityEurope

[Eric van der Helm @EricvdHelm]

I’m looking forward to meeting everyone in Berlin next week, so if you’re also attending @SPRIND feel free to send me a message

[SNIPR @sniprbiome]

Meet SNIPR BIOME next week: Jakob & @EricvdHelm at Venture @SPRIND Berlin (Apr 8), Alice discussing untreatable infections at EU Parliament, and @groendahl & Anders at #ESCMIDGLOBAL Vienna (Apr 10-14). Don't miss our SNIPR001 poster (P2537) Apr 13, 12:00–13:30, Hall D!

[SNIPR @sniprbiome]

SNIPR Biome strengthens IP portfolio with a patent granted for a novel #CRISPR-Cas system! Read more in the press release below.

[Sri Kosuri @srikosuri]

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases.

I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known.

People can contact me directly at my first name (as written in my profile) at https://t.co/ubo0zQRMn0.

[Eric van der Helm @EricvdHelm]

On February 25-26, @groendahl and I will be in Basel for the #AMRConference. We’re excited to discuss how @sniprbiome CRISPR technology can help combat #AntimicrobialResistance. If you're attending, feel free to reach out via [email protected]

[SNIPR @sniprbiome]

Attending #JPM2025 this January? @groendahl and @EricvdHelm will be present and involved in JPM week events. Reach out if you want to meet in San Francisco!

[Eric van der Helm @EricvdHelm]

Seven days to #BioEurope! Reach out if you are at #BioEurope and want to know more about @sniprbiome progress in AMR and Microbial Gene Therapy.

[Eric van der Helm @EricvdHelm]

Want to know more about building large #phage libraries using cell-free synthesis? Check out our new @sniprbiome scientific article in @OUPSynBio. Big congrats to PhD student Camilla Schoopp Kristensen for leading this work.

[SNIPR @sniprbiome]

🧬 New publication alert! Our team has just published a new article on advancing bacteriophage engineering in the @OUPSynBio. Congratulations to authors Camilla Kristensen, Anders Østergaard, Mogens Kilstrup (@DTUbioengineer), @EricvdHelm & Adam Takos. https://t.co/4GGqPheezE

[Eric van der Helm @EricvdHelm]

Great to see David Baker’s groundbreaking work recognized with the 2024 Nobel Prize in Chemistry. It was an incredible experience to have worked in his lab at the @UWproteindesign over a decade ago and to see the work he's been honored for today!

[The Nobel Prize @NobelPrize]

BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”

[SNIPR @sniprbiome]

We are pleased to share that SNIPR Biome has received funding from the @gatesfoundation to advance our microbial gene therapy platform aimed at improving Environmental Enteric Dysfunction in pregnant women from low- and middle-income countries (LMICs). https://t.co/lPNgXLKzUx

[Unveil Bio @UnveilBio]

One of the many perks as an Unveil Bio customer:
Edible plasmids!

Get your plasmids sequenced at https://t.co/mCWLXOvChX

[SNIPR @sniprbiome]

Exciting news: SNIPR Biome receives funding from @CARB_X to support advancement of CRISPR-medicine SNIPR001 into Phase 1b/2a clinical trials in haematological cancer patients! 👇https://t.co/rfVsArifR9

[Nature Portfolio @NaturePortfolio]

A study in @NatureComms explores the distribution, evolution and functions of the K1 capsule at a population level and its important role in the pathogenesis of E. coli. https://t.co/BVjs06FQdn